These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 1870701)

  • 1. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease.
    Mavridis M; Degryse AD; Lategan AJ; Marien MR; Colpaert FC
    Neuroscience; 1991; 41(2-3):507-23. PubMed ID: 1870701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An immunohistochemical study of the acute and long-term effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset.
    Waters CM; Hunt SP; Jenner P; Marsden CD
    Neuroscience; 1987 Dec; 23(3):1025-39. PubMed ID: 2893993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus.
    Mitchell IJ; Cross AJ; Sambrook MA; Crossman AR
    Neurosci Lett; 1985 Oct; 61(1-2):195-200. PubMed ID: 3878482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study.
    Herkenham M; Little MD; Bankiewicz K; Yang SC; Markey SP; Johannessen JN
    Neuroscience; 1991; 40(1):133-58. PubMed ID: 2052148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alterations in multiple tyrosine hydroxylase mRNAs in the substantia nigra, locus coeruleus and adrenal gland of MPTP-treated parkinsonian monkeys.
    Ohye T; Ichinose H; Ogawa M; Yoshida M; Nagatsu T
    Neurodegeneration; 1995 Mar; 4(1):81-5. PubMed ID: 7600187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI detects acute degeneration of the nigrostriatal dopamine system after MPTP exposure in hemiparkinsonian monkeys.
    Miletich RS; Bankiewicz KS; Quarantelli M; Plunkett RJ; Frank J; Kopin IJ; Di Chiro G
    Ann Neurol; 1994 Jun; 35(6):689-97. PubMed ID: 8210225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey.
    Pifl C; Schingnitz G; Hornykiewicz O
    Neuroscience; 1991; 44(3):591-605. PubMed ID: 1754053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes.
    Oiwa Y; Eberling JL; Nagy D; Pivirotto P; Emborg ME; Bankiewicz KS
    Front Biosci; 2003 Sep; 8():a155-66. PubMed ID: 12957824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs.
    Colpaert FC; Degryse AD; Van Craenendonck HV
    Brain Res Bull; 1991 Apr; 26(4):627-31. PubMed ID: 1678307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons.
    German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK
    Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.
    Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y
    Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons.
    Hantraye P; Varastet M; Peschanski M; Riche D; Cesaro P; Willer JC; Maziere M
    Neuroscience; 1993 Mar; 53(1):169-78. PubMed ID: 8469305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Bezard E; Dovero S; Prunier C; Ravenscroft P; Chalon S; Guilloteau D; Crossman AR; Bioulac B; Brotchie JM; Gross CE
    J Neurosci; 2001 Sep; 21(17):6853-61. PubMed ID: 11517273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP.
    Schneider JS; Yuwiler A; Markham CH
    Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R; Kito S; Ishida H; Katayama S
    Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.